Effect of Pravastatin as an Adjunctive Therapeutic for Mitral Insufficiency with Hyperlipidemia in a Dog

Table 1

Hematological, serum biochemical, and cardiac biomarker parameters after pravastatin administration.

Variables	Reference	Time (days)
	Range	0	11	30	45	65	96	121	150	211	283	375
White blood cells (×10^3/mm^3)	6 − 17	12.0	—	10.1	—	11.1	10.7	8.7	9.1	10.6	9.4	11.2
Red blood cells (×10^4/mm^3)	550−850	652	—	656	—	723	758	645	718	676	695	686
Packed cell volume (%)	37−55	45.1	—	45.1	—	49.9	51.6	44.3	49.9	46.4	47.3	47.0
Alanine aminotransferase (U/L)	10−100	59	—	102	—	109	112	118	123	105	92	98
Aspartate aminotransferase (U/L)	0 − 50	22	—	25	—	27	28	24	30	29	28	30
Alkaline phosphatase (U/L)	23−212	443	—	297	—	319	361	330	367	303	244	242
Blood urea nitrogen (mg/dL)	7 − 27	14.3	—	16.3	—	17.2	13.4	17.7	19.9	17.2	14.4	18.2
Creatinine (mg/dL)	0.5 − 1.8	0.6	—	0.8	—	0.8	0.8	0.6	0.6	0.7	0.8	0.7
Triglyceride (mg/dL)	17−79	577	396	180	178	424	402	209	205	263	162	294
Total cholesterol (mg/dL)	111−320	360	281	274	273	279	295	295	317	256	253	239
Creatine kinase (U/L)	10−200	60	75	69	75	98	75	63	70	79	75	166
Serum N-terminal probrain natriuretic peptide (pmol/L)	<900	2449	1352	1117	1402	1305	1209	1020	1058	988	2704	2146